

12-Quarter Financial Information



For the Quarters Ended On	September 2026	June 2026	March 2026	December 2025	September 2025	June 2025	March 2025	December 2024	September 2024	June 2024	March 2024	December 2023
Comparative Income Statements												
Net Sales	\$ 1,019.1	\$ 1,026.5	\$ 982.9	\$ 962.7	\$ 961.1	\$ 966.0	\$ 887.3	\$ 848.1	\$ 909.3	\$ 910.1	\$ 915.4	\$ 838.5
Gross Margin	\$ 372.9	\$ 365.5	\$ 351.9	\$ 338.2	\$ 363.1	\$ 367.0	\$ 336.4	\$ 329.4	\$ 350.8	\$ 342.6	\$ 332.7	\$ 312.3
Gross Margin % of Sales	36.6%	35.6%	35.8%	35.1%	37.8%	38.0%	37.9%	38.8%	38.6%	37.6%	36.3%	37.2%
Selling, Research & Development and Administrative % of Sales	\$ 160.2	\$ 157.7	\$ 167.6	\$ 151.3	\$ 148.8	\$ 151.1	\$ 155.3	\$ 138.5	\$ 141.6	\$ 149.3	\$ 152.8	\$ 138.3
Depreciation and Amortization	\$ 75.5	\$ 79.6	\$ 75.7	\$ 76.6	\$ 75.2	\$ 69.9	\$ 65.6	\$ 67.5	\$ 67.0	\$ 65.0	\$ 64.3	\$ 64.4
Depreciation and Amortization % of Sales	7.4%	7.8%	7.7%	8.0%	7.8%	7.2%	7.4%	8.0%	7.4%	7.1%	7.0%	7.7%
Interest Expense	\$ 15.8	\$ 16.0	\$ 16.9	\$ 17.0	\$ 13.5	\$ 10.9	\$ 11.4	\$ 11.4	\$ 12.3	\$ 10.1	\$ 10.2	\$ 10.5
Interest Expense % of Sales	1.5%	1.6%	1.7%	1.8%	1.4%	1.1%	1.3%	1.3%	1.4%	1.1%	1.1%	1.3%
Interest Income	\$ 1.9	\$ 2.8	\$ 3.6	\$ 4.6	\$ 2.4	\$ 1.9	\$ 2.8	\$ 3.1	\$ 3.0	\$ 3.1	\$ 2.9	\$ 2.1
Interest Income % of Sales	0.2%	0.3%	0.4%	0.5%	0.2%	0.2%	0.3%	0.4%	0.3%	0.3%	0.3%	0.3%
Net Income	\$ 32.6	\$ 87.6	\$ 72.7	\$ 74.3	\$ 127.9	\$ 111.7	\$ 78.8	\$ 100.9	\$ 100.0	\$ 90.5	\$ 83.1	\$ 62.4
Financial Metrics												
Core Sales Growth %	5%	1%	0%	5%	1%	3%	0%	2%	2%	3%	5%	2%
Adjusted EPS	\$ 1.52	\$ 1.42	\$ 1.19	\$ 1.25	\$ 1.62	\$ 1.66	\$ 1.20	\$ 1.52	\$ 1.49	\$ 1.37	\$ 1.26	\$ 1.21
Adjusted EBITDA	\$ 217.2	\$ 212.6	\$ 188.9	\$ 190.8	\$ 222.6	\$ 218.4	\$ 183.3	\$ 194.9	\$ 208.4	\$ 192.8	\$ 178.8	\$ 179.4
Adjusted EBITDA Margin	21.3%	20.7%	19.2%	19.8%	23.2%	22.6%	20.7%	23.0%	22.9%	21.2%	19.5%	21.4%
Effective Tax Rate	45.6%	23.5%	22.4%	18.9%	17.1%	20.0%	25.8%	13.1%	23.8%	23.5%	20.5%	22.8%
Comparative Balance Sheets												
Cash, Equivalents and Short-Term Investments	\$ 212.3	\$ 197.3	\$ 229.5	\$ 409.5	\$ 264.8	\$ 169.8	\$ 136.8	\$ 226.2	\$ 327.9	\$ 223.9	\$ 201.1	\$ 223.6
Accounts and Notes Receivable, less ADA	\$ 883.9	\$ 897.7	\$ 833.3	\$ 803.8	\$ 799.0	\$ 800.2	\$ 742.7	\$ 658.1	\$ 699.0	\$ 737.8	\$ 724.0	\$ 677.8
Inventories	\$ 582.6	\$ 580.1	\$ 551.5	\$ 537.8	\$ 547.3	\$ 527.4	\$ 483.5	\$ 461.8	\$ 488.5	\$ 484.6	\$ 496.8	\$ 513.1
Total Current Assets	\$ 1,836.8	\$ 1,834.8	\$ 1,768.3	\$ 1,893.6	\$ 1,783.6	\$ 1,663.0	\$ 1,511.8	\$ 1,478.4	\$ 1,665.6	\$ 1,593.7	\$ 1,560.0	\$ 1,549.3
Property, Plant and Equipment, Net	\$ 1,635.5	\$ 1,646.0	\$ 1,660.9	\$ 1,676.5	\$ 1,639.6	\$ 1,584.5	\$ 1,489.4	\$ 1,447.2	\$ 1,505.2	\$ 1,466.3	\$ 1,464.4	\$ 1,478.1
Total Assets	\$ 5,111.6	\$ 5,133.2	\$ 5,097.8	\$ 5,252.7	\$ 5,100.8	\$ 4,865.4	\$ 4,527.1	\$ 4,432.3	\$ 4,625.2	\$ 4,453.3	\$ 4,437.1	\$ 4,451.9
Accounts Payable, Accrued and Other Liabilities	\$ 872.1	\$ 887.3	\$ 840.9	\$ 822.9	\$ 844.6	\$ 817.4	\$ 762.6	\$ 730.0	\$ 773.5	\$ 762.4	\$ 760.8	\$ 793.1
Total Current Liabilities	\$ 1,222.8	\$ 1,136.5	\$ 1,063.0	\$ 1,166.4	\$ 1,499.2	\$ 1,368.9	\$ 1,208.0	\$ 1,068.3	\$ 1,026.7	\$ 1,168.1	\$ 1,196.1	\$ 1,251.3
Long-Term Debt, Net	\$ 1,024.7	\$ 1,118.4	\$ 1,143.4	\$ 1,139.4	\$ 546.0	\$ 535.1	\$ 561.2	\$ 688.1	\$ 822.7	\$ 681.5	\$ 680.4	\$ 681.2
Total Liabilities	\$ 2,450.4	\$ 2,458.8	\$ 2,423.5	\$ 2,540.5	\$ 2,288.8	\$ 2,147.6	\$ 1,975.6	\$ 1,946.4	\$ 2,071.6	\$ 2,043.0	\$ 2,074.2	\$ 2,130.6
Total Stockholders' Equity	\$ 2,633.1	\$ 2,646.7	\$ 2,647.6	\$ 2,686.0	\$ 2,787.5	\$ 2,717.8	\$ 2,551.5	\$ 2,485.9	\$ 2,553.6	\$ 2,410.2	\$ 2,362.9	\$ 2,321.3
Cash Flows												
Net Cash Provided by Operations	\$ 167.6	\$ 103.5	\$ 118.7	\$ 183.7	\$ 177.6	\$ 126.0	\$ 82.7	\$ 178.2	\$ 229.3	\$ 143.6	\$ 92.3	\$ 219.6
Capital Expenditures less Government Grants	\$ 69.0	\$ 57.6	\$ 65.4	\$ 86.8	\$ 63.3	\$ 60.1	\$ 56.9	\$ 66.1	\$ 66.6	\$ 68.2	\$ 75.7	\$ 81.1
Free Cash Flow	\$ 98.6	\$ 45.9	\$ 53.3	\$ 96.9	\$ 114.3	\$ 65.8	\$ 25.9	\$ 112.2	\$ 162.7	\$ 75.4	\$ 16.7	\$ 138.5
Dividends Paid	\$ 30.5	\$ 30.6	\$ 30.9	\$ 31.5	\$ 29.6	\$ 29.7	\$ 29.9	\$ 29.9	\$ 29.9	\$ 27.2	\$ 27.1	\$ 27.0
Purchase of Treasury Stock	\$ 30.0	\$ 50.0	\$ 100.0	\$ 175.0	\$ 40.0	\$ 70.0	\$ 80.0	\$ 37.3	\$ 14.2	\$ 5.1	\$ 12.1	\$ 10.3
Aptar Pharma												
Net Sales	\$ 454.0	\$ 458.2	\$ 438.6	\$ 440.0	\$ 445.4	\$ 442.6	\$ 409.5	\$ 400.7	\$ 420.6	\$ 414.5	\$ 407.3	\$ 385.1
Core Sales Growth %	1%	1%	-1%	4%	2%	3%	3%	4%	7%	7%	13%	11%
Adjusted EBITDA	\$ 165.1	\$ 153.9	\$ 146.2	\$ 142.6	\$ 165.8	\$ 156.8	\$ 142.5	\$ 143.1	\$ 151.6	\$ 141.5	\$ 132.2	\$ 131.1
Adjusted EBITDA Margin	36.4%	33.6%	33.3%	32.4%	37.2%	35.4%	34.8%	35.7%	36.0%	34.1%	32.5%	34.1%
Aptar Beauty												
Net Sales	\$ 357.4	\$ 367.5	\$ 363.6	\$ 341.1	\$ 327.8	\$ 334.8	\$ 305.7	\$ 274.1	\$ 302.9	\$ 321.5	\$ 327.3	\$ 287.7
Core Sales Growth %	8%	1%	3%	10%	0%	1%	-3%	-3%	-6%	-1%	-1%	-6%
Adjusted EBITDA	\$ 40.7	\$ 44.7	\$ 40.5	\$ 34.8	\$ 39.7	\$ 47.1	\$ 37.1	\$ 33.9	\$ 40.2	\$ 44.6	\$ 41.1	\$ 42.3
Adjusted EBITDA Margin	11.4%	12.2%	11.1%	10.2%	12.1%	14.1%	12.1%	12.4%	13.3%	13.9%	12.6%	14.7%
Aptar Closures												
Net Sales	\$ 207.8	\$ 200.9	\$ 180.7	\$ 181.6	\$ 188.0	\$ 188.6	\$ 172.1	\$ 173.3	\$ 185.8	\$ 174.0	\$ 180.8	\$ 165.7
Core Sales Growth %	11%	4%	0%	1%	-1%	7%	-2%	7%	4%	0%	1%	-4%
Adjusted EBITDA	\$ 32.2	\$ 29.8	\$ 23.7	\$ 27.0	\$ 30.3	\$ 31.9	\$ 27.3	\$ 27.9	\$ 32.0	\$ 27.1	\$ 27.2	\$ 22.3
Adjusted EBITDA Margin	15.5%	14.9%	13.1%	14.9%	16.1%	16.9%	15.8%	16.1%	17.2%	15.6%	15.0%	13.5%

Notes and Reconciliations:

Document Notes:

This document is a compiled summary of selected financial information extracted from Aptar's prior twelve quarters of Form 10-Q filings and should be read together with the Company's full SEC filings, which contain important footnotes and context. It is provided solely for the convenience of users to facilitate period-over-period comparison. While care has been taken to ensure the information is accurate as of the dates of the original filings, this compilation does not replace or supersede the complete financial statements and disclosures contained in Aptar's SEC filings.

For comprehensive information, including footnotes and management's discussion and analysis, users should refer to the Company's full Form 10-Q and Form 10-K filings available on the SEC's website and the Company's Investor Relations page.

Quarterly cash flow amounts for interim periods are derived from cumulative year-to-date amounts reported in the applicable Form 10-Q and therefore may not represent amounts separately presented in the Company's SEC filings.

Presentation of Non-GAAP Information:

This press release refers to certain non-GAAP financial measures, including current year adjusted earnings per share and adjusted EBITDA, which exclude the impact of restructuring initiatives, acquisition-related costs, certain purchase accounting adjustments related to acquisitions and investments and net unrealized investment gains and losses related to observable market price changes on equity securities, Russia deconsolidation impact, and other special items. Core sales and adjusted earnings per share also neutralize the impact of foreign currency translation effects when comparing current results to the prior year. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities, Russia deconsolidation impacts, and other special items. For the three and nine months specifically: lawsuits

between Aptar and ARS Pharmaceuticals, Inc., involving Aptar's claims of trade-secret misappropriation and contractual breaches and ARS's lawsuit against Aptar under U.S. antitrust laws; and patent infringement actions filed by Nemera La Verpillière SAS in Germany and France relating to certain of Aptar's ophthalmic products. These costs are excluded because they do not reflect our core operating performance. Please refer to "Legal Proceedings" within Note 13 - Commitments and Contingencies within Aptar's Form 10-K for the year ended December 31, 2025 and subsequent SEC filings for more information. Adjusted EBITDA margin is adjusted EBITDA divided by reported net sales. Non-GAAP financial measures may not be comparable to similarly titled non-GAAP financial measures provided by other companies. Aptar's management believes these non-GAAP financial measures provide useful information to our investors because they allow for a better period over period comparison of operating results by removing the impact of items that, in management's view, do not reflect Aptar's core operating performance. These non-GAAP financial measures also provide investors with certain information used by Aptar's management when making financial and operational decisions. Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial results but should be read in conjunction with the unaudited condensed consolidated statements of income and other information presented herein. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is included in the accompanying tables. Our outlook is provided on a non-GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of the company's routine activities, such as restructuring, acquisition costs and other special items.

12-Quarter Financial Information



Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)	September 2026	June 2026	March 2026	December 2025	September 2025	June 2025	March 2025	December 2024	September 2024	June 2024	March 2024	December 2023
AptarGroup, Inc.												
Net Sales	\$ 1,019.1	\$ 1,026.5	\$ 982.9	\$ 962.7	\$ 961.1	\$ 966.0	\$ 887.3	\$ 848.1	\$ 909.3	\$ 910.1	\$ 915.4	\$ 838.5
Reported net income	\$ 32.8	\$ 88.0	\$ 72.8	\$ 74.3	\$ 127.8	\$ 111.7	\$ 78.7	\$ 100.9	\$ 99.9	\$ 90.5	\$ 82.9	\$ 62.2
Reported income taxes	\$ 27.5	\$ 27.0	\$ 21.0	\$ 17.3	\$ 26.3	\$ 28.0	\$ 27.4	\$ 15.2	\$ 31.2	\$ 27.8	\$ 21.4	\$ 18.4
Reported income before income taxes	\$ 60.3	\$ 115.0	\$ 93.8	\$ 91.5	\$ 154.1	\$ 139.7	\$ 106.0	\$ 116.1	\$ 131.1	\$ 118.2	\$ 104.3	\$ 80.6
Adjustments:												
Restructuring initiatives	\$ 2.2	\$ 1.4	\$ 1.1	\$ 4.0	\$ 2.2	\$ 1.6	\$ 2.0	\$ 3.3	\$ 3.9	\$ 2.3	\$ 3.5	\$ 25.4
Curtailment gain related to restructuring initiatives	\$ -	\$ -	\$ -	\$ (0.1)	\$ -	\$ -	\$ -	\$ -	\$ (1.9)	\$ -	\$ -	\$ -
Net investment (gain) loss	\$ 1.0	\$ (0.9)	\$ 1.1	\$ 1.3	\$ 0.2	\$ (2.1)	\$ 1.1	\$ (0.2)	\$ (1.0)	\$ 0.1	\$ (0.6)	\$ 0.4
Realized gain on investments included in net investment (gain) loss above	\$ -	\$ 0.1	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Gain from remeasurement of equity method investment	\$ -	\$ -	\$ -	\$ -	\$ (26.5)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Transaction costs related to acquisitions	\$ -	\$ 0.0	\$ 0.0	\$ 0.4	\$ 0.7	\$ 0.3	\$ -	\$ -	\$ -	\$ 0.1	\$ -	\$ 0.2
Purchase accounting adjustments related to acquisitions and investments	\$ -	\$ -	\$ 0.1	\$ 0.6	\$ 1.1	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Russia Deconsolidation Impacts	\$ 61.2	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Other special items	\$ 3.1	\$ 4.1	\$ 3.7	\$ 4.0	\$ 4.4	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Adjusted earnings before income taxes	\$ 127.8	\$ 119.7	\$ 99.9	\$ 101.8	\$ 136.2	\$ 139.5	\$ 109.2	\$ 119.2	\$ 132.1	\$ 120.8	\$ 107.2	\$ 106.7
Interest expense	\$ 15.8	\$ 16.0	\$ 16.9	\$ 17.0	\$ 13.5	\$ 10.9	\$ 11.4	\$ 11.4	\$ 12.3	\$ 10.1	\$ 10.2	\$ 10.5
Interest income	\$ (1.9)	\$ (2.8)	\$ (3.6)	\$ (4.6)	\$ (2.4)	\$ (1.9)	\$ (2.8)	\$ (3.1)	\$ (3.0)	\$ (3.1)	\$ (2.9)	\$ (2.1)
Adjusted earnings before net interest and taxes (Adjusted EBIT)	\$ 141.7	\$ 132.9	\$ 113.2	\$ 114.2	\$ 147.4	\$ 148.5	\$ 117.7	\$ 127.5	\$ 141.4	\$ 127.8	\$ 114.5	\$ 115.1
Depreciation and amortization	\$ 75.5	\$ 79.6	\$ 75.7	\$ 76.6	\$ 75.2	\$ 69.9	\$ 65.6	\$ 67.5	\$ 67.0	\$ 65.0	\$ 64.3	\$ 64.4
Adjusted EBITDA	\$ 217.2	\$ 212.6	\$ 188.9	\$ 190.8	\$ 222.6	\$ 218.4	\$ 183.3	\$ 194.9	\$ 208.4	\$ 192.8	\$ 178.8	\$ 179.4
Adjusted EBITDA %	21.3%	20.7%	19.2%	19.8%	23.2%	22.6%	20.7%	23.0%	22.9%	21.2%	19.5%	21.4%
Aptar Pharma												
Net Sales	\$ 454.0	\$ 458.2	\$ 438.6	\$ 440.0	\$ 445.4	\$ 442.6	\$ 409.5	\$ 400.7	\$ 420.6	\$ 414.5	\$ 407.3	\$ 385.1
Reported net income	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Reported income taxes	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Reported income before income taxes	\$ 122.6	\$ 110.6	\$ 106.7	\$ 102.6	\$ 124.8	\$ 122.6	\$ 111.1	\$ 111.9	\$ 120.2	\$ 111.8	\$ 103.4	\$ 99.8
Adjustments:												
Restructuring initiatives	\$ 0.4	\$ (0.1)	\$ 0.0	\$ (0.1)	\$ 0.9	\$ 0.1	\$ 0.2	\$ (0.1)	\$ 0.6	\$ 0.1	\$ 0.0	\$ 3.2
Curtailment gain related to restructuring initiatives	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Net investment (gain) loss	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Realized gain on investments included in net investment (gain) loss above	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Gain from remeasurement of equity method investment	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Transaction costs related to acquisitions	\$ -	\$ 0.0	\$ 0.0	\$ 0.4	\$ 0.6	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Purchase accounting adjustments related to acquisitions and investments	\$ -	\$ -	\$ 0.1	\$ 0.1	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Russia Deconsolidation Impacts	\$ 3.1	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Other special items	\$ 3.1	\$ 4.1	\$ 3.7	\$ 4.0	\$ 4.4	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Adjusted earnings before income taxes	\$ 129.2	\$ 114.6	\$ 110.6	\$ 106.9	\$ 130.7	\$ 122.7	\$ 111.3	\$ 111.9	\$ 120.8	\$ 111.9	\$ 103.4	\$ 103.0
Interest expense	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Interest income	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Adjusted earnings before net interest and taxes (Adjusted EBIT)	\$ 129.2	\$ 114.6	\$ 110.6	\$ 106.9	\$ 130.7	\$ 122.7	\$ 111.3	\$ 111.9	\$ 120.8	\$ 111.9	\$ 103.4	\$ 103.0
Depreciation and amortization	\$ 35.9	\$ 39.3	\$ 35.6	\$ 35.7	\$ 35.1	\$ 34.2	\$ 31.1	\$ 31.2	\$ 30.8	\$ 29.6	\$ 28.8	\$ 28.1
Adjusted EBITDA	\$ 165.1	\$ 153.9	\$ 146.2	\$ 142.6	\$ 165.8	\$ 156.8	\$ 142.5	\$ 143.1	\$ 151.6	\$ 141.5	\$ 132.2	\$ 131.1
Adjusted EBITDA %	36.4%	33.6%	33.3%	32.4%	37.2%	35.4%	34.8%	35.7%	36.0%	34.1%	32.5%	34.1%
Aptar Beauty												
Net Sales	\$ 357.4	\$ 367.5	\$ 363.6	\$ 341.1	\$ 327.8	\$ 334.8	\$ 305.7	\$ 274.1	\$ 302.9	\$ 321.5	\$ 327.3	\$ 287.7
Reported net income	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Reported income taxes	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Reported income before income taxes	\$ 5.4	\$ 18.6	\$ 14.5	\$ 6.1	\$ 40.1	\$ 24.6	\$ 16.7	\$ 11.0	\$ 17.8	\$ 22.8	\$ 17.2	\$ 12.6
Adjustments:												
Restructuring initiatives	\$ 1.8	\$ 1.4	\$ 1.3	\$ 2.9	\$ 0.6	\$ 0.6	\$ 0.4	\$ 2.2	\$ 2.0	\$ 1.2	\$ 2.7	\$ 8.0
Curtailment gain related to restructuring initiatives	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Net investment (gain) loss	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Realized gain on investments included in net investment (gain) loss above	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Gain from remeasurement of equity method investment	\$ -	\$ -	\$ -	\$ -	\$ (26.5)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Transaction costs related to acquisitions	\$ -	\$ -	\$ -	\$ -	\$ 0.2	\$ 0.3	\$ -	\$ -	\$ -	\$ 0.1	\$ -	\$ 0.2
Purchase accounting adjustments related to acquisitions and investments	\$ -	\$ -	\$ -	\$ 0.6	\$ 1.1	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Russia Deconsolidation Impacts	\$ 9.6	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Other special items	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Adjusted earnings before income taxes	\$ 16.7	\$ 20.0	\$ 15.8	\$ 9.6	\$ 15.4	\$ 25.6	\$ 17.1	\$ 13.2	\$ 19.8	\$ 24.1	\$ 19.9	\$ 20.8
Interest expense	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Interest income	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Adjusted earnings before net interest and taxes (Adjusted EBIT)	\$ 16.7	\$ 20.0	\$ 15.8	\$ 9.6	\$ 15.4	\$ 25.6	\$ 17.1	\$ 13.2	\$ 19.8	\$ 24.1	\$ 19.9	\$ 20.8
Depreciation and amortization	\$ 24.0	\$ 24.8	\$ 24.7	\$ 25.2	\$ 24.3	\$ 21.5	\$ 20.1	\$ 20.8	\$ 20.4	\$ 20.5	\$ 21.2	\$ 21.5
Adjusted EBITDA	\$ 40.7	\$ 44.7	\$ 40.5	\$ 34.8	\$ 39.7	\$ 47.1	\$ 37.1	\$ 33.9	\$ 40.2	\$ 44.6	\$ 41.1	\$ 42.3
Adjusted EBITDA %	11.4%	12.2%	11.1%	10.2%	12.1%	14.1%	12.1%	12.4%	13.3%	13.9%	12.6%	14.7%
Aptar Closures												
Net Sales	\$ 207.8	\$ 200.9	\$ 180.7	\$ 181.6	\$ 188.0	\$ 188.6	\$ 172.1	\$ 173.3	\$ 185.8	\$ 174.0	\$ 180.8	\$ 165.7
Reported net income	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Reported income taxes	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Reported income before income taxes	\$ (23.0)	\$ 15.2	\$ 9.2	\$ 11.7	\$ 14.7	\$ 17.5	\$ 12.3	\$ 11.9	\$ 18.0	\$ 12.0	\$ 12.9	\$ (5.6)
Adjustments:												
Restructuring initiatives	\$ (0.0)	\$ 0.1	\$ 0.2	\$ 0.6	\$ 0.7	\$ 0.9	\$ 1.4	\$ 1.3	\$ 0.9	\$ 0.9	\$ 0.8	\$ 13.9
Curtailment gain related to restructuring initiatives	\$ -	\$ -	\$ -	\$ (0.1)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Net investment (gain) loss	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Realized gain on investments included in net investment (gain) loss above	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Gain from remeasurement of equity method investment	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Transaction costs related to acquisitions	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Purchase accounting adjustments related to acquisitions and investments	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Russia Deconsolidation Impacts	\$ 40.6	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Other special items	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ (1.9)	\$ -	\$ -	\$ -
Adjusted earnings before income taxes	\$ 17.6	\$ 15.3	\$ 9.4	\$ 12.2	\$ 15.4	\$ 18.4	\$ 13.7	\$ 13.3	\$ 17.1	\$ 12.9	\$ 13.6	\$ 8.3
Interest expense	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Interest income	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Adjusted earnings before net interest and taxes (Adjusted EBIT)	\$ 17.6	\$ 15.3	\$ 9.4	\$ 12.2	\$ 15.4	\$ 18.4	\$ 13.7	\$ 13.3	\$ 17.1	\$ 12.9	\$ 13.6	\$ 8.3
Depreciation and amortization	\$ 14.6	\$ 14.5	\$ 14.2	\$ 14.8	\$ 14.9	\$ 13.4	\$ 13.6	\$ 14.6	\$ 14.9	\$ 14.3	\$ 13.5	\$ 14.0
Adjusted EBITDA	\$ 32.2	\$ 29.8	\$ 23.7	\$ 27.0	\$ 30.3	\$ 31.9	\$ 27.3	\$ 27.9	\$ 32.0	\$ 27.1	\$ 27.2	\$ 22.3
Adjusted EBITDA %	15.5%	14.9%	13.1%	14.9%	16.1%	16.9%	15.8%	16.1%	17.2%	15.6%	15.0%	13.5%

12-Quarter Financial Information



Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)	September 2026	June 2026	March 2026	December 2025	September 2025	June 2025	March 2025	December 2024	September 2024	June 2024	March 2024	December 2023
AptarGroup, Inc.												
Income Before Income Taxes	\$ 60.3	\$ 115.0	\$ 93.8	\$ 91.5	\$ 154.1	\$ 139.7	\$ 106.0	\$ 116.1	\$ 131.1	\$ 118.2	\$ 104.3	\$ 80.6
Adjustments:												
Restructuring Initiatives	\$ 2.2	\$ 1.4	\$ 1.1	\$ 4.0	\$ 2.2	\$ 1.6	\$ 2.0	\$ 3.3	\$ 3.9	\$ 2.3	\$ 3.5	\$ 25.4
Net Investment (Gain) / Loss	\$ 1.0	\$ (0.9)	\$ 1.1	\$ 1.3	\$ 0.2	\$ (2.1)	\$ 1.1	\$ (0.2)	\$ (1.0)	\$ 0.1	\$ (0.6)	\$ 0.4
Gain from Remeasurement of Equity Method Investment	\$ -	\$ -	\$ -	\$ -	\$ (26.5)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Curtailment gain related to restructuring initiatives	\$ -	\$ -	\$ -	\$ (0.1)	\$ -	\$ -	\$ -	\$ -	\$ (1.9)	\$ -	\$ -	\$ -
Realized (Gain) / Loss included in Net Investment (Gain) / Loss above	\$ -	\$ 0.1	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Transaction Costs Related to Acquisitions	\$ -	\$ 0.0	\$ 0.0	\$ 0.4	\$ 0.7	\$ 0.3	\$ -	\$ -	\$ -	\$ 0.1	\$ -	\$ 0.2
Purchase Accounting Adjustments Related to Acquisitions and Investments	\$ -	\$ -	\$ 0.1	\$ 0.6	\$ 1.1	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Russia Deconsolidation Impacts	\$ 61.2	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Other Special Items	\$ 3.1	\$ 4.1	\$ 3.7	\$ 4.0	\$ 4.4	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Foreign Currency Effects	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Adjusted Earnings Before Income Taxes	\$ 127.8	\$ 119.7	\$ 99.9	\$ 101.8	\$ 136.2	\$ 139.5	\$ 109.2	\$ 119.2	\$ 132.1	\$ 120.8	\$ 107.2	\$ 106.7
Provision for Income Taxes	\$ 27.5	\$ 27.0	\$ 21.0	\$ 17.3	\$ 26.3	\$ 28.0	\$ 27.4	\$ 15.2	\$ 31.2	\$ 27.8	\$ 21.4	\$ 18.4
Adjustments:												
Net effect of items included in the Provision for Income Taxes	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Restructuring Initiatives	\$ 0.6	\$ 0.4	\$ 0.3	\$ 1.0	\$ 0.6	\$ 0.4	\$ 0.5	\$ 0.9	\$ 1.0	\$ 0.6	\$ 0.9	\$ 6.8
Net Investment (Gain) / Loss	\$ 0.2	\$ (0.2)	\$ 0.3	\$ 0.3	\$ 0.0	\$ (0.5)	\$ 0.3	\$ (0.1)	\$ (0.3)	\$ 0.0	\$ (0.1)	\$ 0.1
Gain from Remeasurement of Equity Method Investment	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Curtailment gain related to restructuring initiatives	\$ -	\$ -	\$ -	\$ (0.0)	\$ -	\$ -	\$ -	\$ (0.5)	\$ -	\$ -	\$ -	\$ -
Realized (Gain) / Loss included in Net Investment (Gain) / Loss above	\$ -	\$ 0.0	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Transaction Costs Related to Acquisitions	\$ -	\$ 0.0	\$ 0.0	\$ 0.1	\$ 0.2	\$ 0.1	\$ -	\$ -	\$ -	\$ 0.0	\$ -	\$ 0.1
Purchase Accounting Adjustments Related to Acquisitions and Investments	\$ -	\$ -	\$ 0.0	\$ 0.1	\$ 0.2	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Russia Deconsolidation Impacts	\$ 0.8	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Other Special Items	\$ 0.8	\$ 1.1	\$ 1.0	\$ 1.0	\$ 1.1	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Foreign Currency Effects	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Adjusted Provision for Income Taxes	\$ 29.9	\$ 28.3	\$ 22.6	\$ 19.8	\$ 28.3	\$ 28.0	\$ 28.1	\$ 16.1	\$ 31.5	\$ 28.4	\$ 22.1	\$ 25.3
Net Income/Loss Attributable to Noncontrolling Interests	\$ (0.2)	\$ (0.2)	\$ (0.0)	\$ 0.1	\$ (0.0)	\$ (0.0)	\$ 0.1	\$ 0.1	\$ 0.1	\$ (0.0)	\$ 0.2	\$ 0.1
Net Income Attributable to Redeemable Noncontrolling Interests	\$ 0.0	\$ (0.3)	\$ (0.1)	\$ (0.1)	\$ 0.1	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Net Income Attributable to AptarGroup, Inc.	\$ 32.6	\$ 87.6	\$ 72.7	\$ 74.3	\$ 127.9	\$ 111.7	\$ 78.8	\$ 100.9	\$ 100.0	\$ 90.5	\$ 83.1	\$ 62.4
Adjustments:												
Net effect of items included in the Provision for Income Taxes	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Restructuring Initiatives	\$ 1.7	\$ 1.0	\$ 0.8	\$ 3.0	\$ 1.6	\$ 1.2	\$ 1.5	\$ 2.4	\$ 2.9	\$ 1.7	\$ 2.6	\$ 18.6
Net Investment (Gain) / Loss	\$ 0.8	\$ (0.7)	\$ 0.8	\$ 1.0	\$ 0.1	\$ (1.6)	\$ 0.8	\$ (0.2)	\$ (0.8)	\$ 0.1	\$ (0.4)	\$ 0.3
Gain from Remeasurement of Equity Method Investment	\$ -	\$ -	\$ -	\$ -	\$ (26.5)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Curtailment gain related to restructuring initiatives	\$ -	\$ -	\$ -	\$ (0.1)	\$ -	\$ -	\$ -	\$ -	\$ (1.4)	\$ -	\$ -	\$ -
Realized (Gain) / Loss included in Net Investment (Gain) / Loss above	\$ -	\$ 0.1	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Transaction Costs Related to Acquisitions	\$ -	\$ 0.0	\$ 0.0	\$ 0.2	\$ 0.6	\$ 0.3	\$ -	\$ -	\$ -	\$ 0.1	\$ -	\$ 0.2
Purchase Accounting Adjustments Related to Acquisitions and Investments	\$ -	\$ -	\$ 0.1	\$ 0.5	\$ 1.0	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Russia Deconsolidation Impacts	\$ 60.4	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Other Special Items	\$ 2.3	\$ 3.0	\$ 2.8	\$ 3.0	\$ 3.3	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Foreign Currency Effects	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Adjusted Net Income Attributable to AptarGroup, Inc.	\$ 97.7	\$ 91.0	\$ 77.2	\$ 82.1	\$ 108.0	\$ 111.5	\$ 81.2	\$ 103.2	\$ 100.7	\$ 92.4	\$ 85.2	\$ 81.5
Diluted Shares Outstanding	64,147	64,208	64,834	65,796	66,630	67,048	67,491	67,923	67,716	67,575	67,432	67,131
Adjusted EPS	\$ 1.52	\$ 1.42	\$ 1.19	\$ 1.25	\$ 1.62	\$ 1.66	\$ 1.20	\$ 1.52	\$ 1.49	\$ 1.37	\$ 1.26	\$ 1.21